Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 601–700 of 1,000
Xiao, L., Zhu, H., Shu, J., Gong, D., Zheng, D., & Gao, J. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-021-06137-0 · Cited by 37
Ring, S. S., Cupovic, J., Onder, L., Lütge, M., Perez‐Shibayama, C., Gil‐Cruz, C., Scandella, E., Martin, A. D., Mörbe, U., Hartmann, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25057-w · Cited by 36
Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer
Scales, M. K., Velez-Delgado, A., Steele, N. G., Schrader, H. E., Stabnick, A. M., Yan, W., Soto, N. M. M., Nwosu, Z. C., Johnson, C. N., Zhang, Y., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010315 · Cited by 38
“Fibroblasts also provide metabolic support [8–10], confer chemoresistance [7,11,12], facilitate immunosuppression [13,14], and restrict tumor perfusion via ECM deposition [15–17].”
BackgroundClinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 38
Patsouras, D., Papaxoinis, K., Kostakis, A. I., Safioleas, M. C., Lazaris, A. C., & Nicolopoulou‐Stamati, P. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3259 · Cited by 35
The Tumor Microenvironment: Part 1
Leibovici, J., Itzhaki, O., Huszar, M., & Sinai, J. (2011) · Immunotherapy · doi:10.2217/imt.11.111 · Cited by 39
Zarodniuk, M., Steele, A., Lü, X., Li, J., & Datta, M. (2023) · npj Genomic Medicine · doi:10.1038/s41525-023-00381-w · Cited by 35
“Both extracranial cancer-associated fi broblasts (CAFs) and CAF-derived ECM have been linked to suppression of antitumor immune responses 16 – 18 ; however, evidence supporting their immunosuppressive roles in brain tumors is lacking.”
Kumar, M. M., Davuluri, S., Sridhar, P., Mukherjee, G., Bajpai, A. K., Bafna, U. D., Devi, U. K., Kallur, P. P. R., Kshitish, A. K., & Jayshree, R. S. (2015) · Tumor Biology · doi:10.1007/s13277-015-4257-6 · Cited by 39
Liao, Y., Xing, S., Xu, B., Liu, W., & Zhang, G. (2017) · Oncotarget · doi:10.18632/oncotarget.16274 · Cited by 34
Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma: Can We Learn From Breast Cancer?
Maggio, F. D., & El-Shakankery, K. H. (2020) · Pancreas · doi:10.1097/mpa.0000000000001504 · Cited by 36
Han, X., Zhang, W.-H., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188444 · Cited by 36
Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity
Bota‐Rabassedas, N., Banerjee, P., Niu, Y., Cao, W., Luo, J., Xi, Y., Tan, X., Sheng, K., Ahn, Y., Lee, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109009 · Cited by 34
“…and genetic approaches to target CAFs in preclinical models result in widely disparate effects that range from tumor suppression to tumor promotion (Feig et al., 2013; Kraman et al., 2010; Loeffler et al., 2006; Olive et al., 2009; Özdemir et al., 2014; Provenzano et al., 2012; Su et al., 2018).”
Reikvam, H., Fredly, H., Kittang, A. O., & Bruserud, Ø. (2013) · Toxins · doi:10.3390/toxins5020336 · Cited by 36
“Similar cells are also present in tumors and may then be important for immunoediting during disease development [85].”
BackgroundZi, F., He, J.-S., Li, Y., Wu, C., Wu, W.-J., Yang, Y., Wang, L., He, D.-H., Yang, L., Zhao, Y., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29924 · Cited by 35
“FAP had important role in tumor progression,(17) invasion,(22) metastasis,(21) and immune escape.(20) HEK293 cells and human mammary adenocarcinoma cells MDA-MB-231 cotransfect with FAP cDNA could more easily to form subcutaneous tumors.”
BackgroundNuclear Receptors as Modulators of the Tumor Microenvironment
Sherman, M. H., Downes, M., & Evans, R. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0528 · Cited by 39
“Similarly, ablation of cancer-associated fibroblasts in several mouse models of cancer, via fibroblast activation protein-targeted vaccination (43) or genetic engineering (44), has been shown to reduce”
BackgroundLukešová, Š., Vroblova, V., Tošner, J., Kopecký, J., Sedláková, I., Čermáková, E., Vokurková, D., & Kopecký, O. (2015) · Współczesna Onkologia · doi:10.5114/wo.2015.54388 · Cited by 36
Hanley, C. J., & Thomas, G. J. (2021) · Oncotarget · doi:10.18632/oncotarget.27936 · Cited by 35
Meng, S., Hara, T., Miura, Y., & Ishii, H. (2024) · Cancer Science · doi:10.1111/cas.16285 · Cited by 33
Chondroitin Sulfate Proteoglycan CSPG4 as a Novel Hypoxia-Sensitive Marker in Pancreatic Tumors
Keleg, S., Alexandr, T., Heller, A., Giese, T., Tjaden, C., Ahmad, S. S., Gaida, M. M., Bauer, A. S., Werner, J., & Giese, N. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100178 · Cited by 34
Omoto, T., Kim‐Kaneyama, J., Lei, X., Orimo, A., Ohnishi, K., Yoshihara, K., Miyauchi, A., Li, S., Gao, L., Umemoto, T., et al. (2017) · Oncogene · doi:10.1038/s41388-017-0033-y · Cited by 33
A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
Nederlof, I., Horlings, H. M., Curtis, C. N., & Kok, M. (2021) · Cancers · doi:10.3390/cancers13020316 · Cited by 34
Immunobiology of cancer-associated fibroblasts in the context of radiotherapy
Hellevik, T., Berzaghi, R., Lode, K., Islam, A., & Martínez-Zubiaurre, I. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03112-w · Cited by 33
Targeting Tumour-Associated Fibroblasts in Cancers
Shah, K., Mallik, S. B., Gupta, P. K., & Iyer, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.908156 · Cited by 37
Cancer‐associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?
Aden, D., Zaheer, S., Ahluwalia, H., & Ranga, S. (2023) · Cell Biology International · doi:10.1002/cbin.12004 · Cited by 33
“Further they also demonstrated immunological control of tumor growth in a subcutaneous model of PDAC by depleting FAP expressing cells (Kraman et al., 2010).”
BackgroundDing, Z., Sun, S., Wang, X., Yang, X., Shi, W., Huang, X., Xie, S., Mo, F., Hou, X., Liu, A., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01507-4 · Cited by 34
Jackson, K. W., Christiansen, V. J., Yadav, V. R., Silasi‐Mansat, R., Lupu, F., Awasthi, V., Zhang, R. R., & McKee, P. A. (2015) · Neoplasia · doi:10.1016/j.neo.2014.11.002 · Cited by 36
“[17] Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO,”
BackgroundInfluentialPyfferoen, L., Mestdagh, P., Vergote, K., Cabooter, N. D., Vandesompele, J., Lambrecht, B. N., & Vermaelen, K. Y. (2014) · International Journal of Cancer · doi:10.1002/ijc.28945 · Cited by 33
Delitto, D., Perez, C., Han, S., Gonzalo, D. H., Pham, K., Knowlton, A. E., Graves, C. L., Behrns, K. E., Moldawer, L. L., Thomas, R. M., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1760-y · Cited by 33
Han, S., Ma, C.-X., Hu, M., Wang, Y., Ma, F., Tao, N., & Qin, Z. (2017) · Cell Biochemistry and Function · doi:10.1002/cbf.3290 · Cited by 33
Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 36
“A study has shown that in lung cancer models where the presence of FAP is genetically depleted, this leads to hypoxic necrosis in the tumor in addition to the induction of CD8+ T cell infiltration [197], Recently, researchers at the University of Heidelberg have introduced PET imaging for FAP expression in cancer, pro…”
Luo, F., Mei, Y., Li, Y.-W., Yang, J., Xi, S., Cao, E., Shen, C., Zhou, D., Wang, P., Zhou, D., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf157 · Cited by 33
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 34
Shi, Y., Kong, Z., Liu, P., Hou, G., Wu, J., Ma, W., Cheng, X., & Wang, Y. (2021) · Cells · doi:10.3390/cells10051142 · Cited by 32
de Willige, S. U., Keane, F. M., Bowen, D. G., Malfliet, J. J. M. C., Zhang, H. E., Maneck, B., McCaughan, G. W., Leebeek, F. W. G., Rijken, D. C., & Gorrell, M. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178987 · Cited by 32
Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment
Parayath, N. N., Padmakumar, S., Nair, S. V., Menon, D., & Amiji, M. M. (2019) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-019-00113-6 · Cited by 34
Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines
Wilson, C. H., & Abbott, C. A. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1522 · Cited by 33
Fujisawa, M., Moh-Moh-Aung, A., Zeng, Z., Yoshimura, T., Wani, Y., & Matsukawa, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205494 · Cited by 36
Větvička, D., Sivák, L., Jogdeo, C. M., Kumar, R., Khan, R. I., Yu, H., & Oupický, D. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.020 · Cited by 33
Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
De, P. K., Aske, J. C., Sulaiman, R. A., & Dey, N. (2022) · Cancers · doi:10.3390/cancers14061519 · Cited by 34
Zhou, Z., Hu, Y., Wu, Y., Qi, Q., Wang, J., Chen, L., & Wang, F. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.09.010 · Cited by 31
Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance
Qin, Y., & Xu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053120 · Cited by 31
“Deletion of these cells provides opportunities for immune therapies (100).”
BackgroundKnopf, J. D., Tholen, S., Koczorowska, M. M., Wever, O. D., Biniossek, M. L., & Schilling, O. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.07.013 · Cited by 31
Huang, C., Suen, C., Lin, C., Chien, C., Lee, H.-Y., Chung, K., Tsai, T., Jiaang, W.-T., Hwang, M., & Chen, X. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvr017 · Cited by 31
Geng, F., Guo, J., Guo, Q., Xie, Y., Dong, L., Zhou, Y., Liu, C., Yu, B., Wu, H., Wu, J., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.06.012 · Cited by 32
Onciul, R., Brehar, F.-M., Toader, C., Covache-Busuioc, R.-A., Glavan, L.-A., Bratu, B.-G., Costin, H. P., Dumitrascu, D.-I., Șerban, M., & Ciurea, A. V. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030153 · Cited by 33
“Therapeutic strategies are based on the classic assumption that CAFs act as immunosuppressive agents [296,297].”
BackgroundThe multifaceted role of the stroma in the healthy prostate and prostate cancer
Carlo, E. D., & Sorrentino, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05564-2 · Cited by 33
Thiery, J. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00103 · Cited by 33
Brennen, W. N., Rosen, D. M., Chaux, A., Netto, G. J., Isaacs, J. T., & Denmeade, S. R. (2014) · The Prostate · doi:10.1002/pros.22847 · Cited by 31
“This is supported by studies in which conditional knockout of FAP-expressing cells using diphtheria toxin restored immunological control of tumor growth in a geneticallyengineered mouse model of pancreatic cancer [19].”
BackgroundResultHuman Correlates of Provocative Questions in Pancreatic Pathology
McDonald, O. G., Maitra, A., & Hruban, R. H. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318273f998 · Cited by 32
Qiu, X., Zhang, F.-F., Geng, F., Liu, C., Wang, Y., Xu, P., Lu, Z.-Z., Xie, Y., Wu, H., Chen, Y., et al. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.08.006 · Cited by 30
Ichikawa, T., Aokage, K., Sugano, M., Miyoshi, T., Kojima, M., Fujii, S., Kuwata, T., Ochiai, A., Suzuki, K., Tsuboi, M., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.023 · Cited by 30
Schreiber, H. W., & Rowley, D. A. (2010) · Science · doi:10.1126/science.1198345 · Cited by 30
Nanomedicine as a potent strategy in melanoma tumor microenvironment
Pautu, V., Leonetti, D., Lepeltier, É., Clere, N., & Passirani, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.014 · Cited by 33
Activated Tumor-infiltrating Fibroblasts Predict Worse Prognosis in Breast Cancer Patients
Hu, G., Xu, F., Zhong, K., Wang, S., Huang, L., & Chen, W. (2018) · Journal of Cancer · doi:10.7150/jca.28054 · Cited by 29
“Currently, depletion of activated fibroblasts has been utilized to restrain cancer including colon cancer in preclinical studies, yielding somewhat promising results [5-7].”
BackgroundGarcia‐Vicién, G., Mezheyeuski, A., Bañuls, M., Ruiz-Roig, N., & Molleví, D. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041544 · Cited by 30
A triple enhanced permeable gold nanoraspberry designed for positive feedback interventional therapy
Liu, Y., Ye, Z., Yang, W., Hu, Y., Zhao, Y., Li, Z., Xu, B., Chen, D., Tu, J., & Shen, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.010 · Cited by 29
Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
Smith, C., Zheng, W., Dong, J., Wang, Y., Lai, J., Liu, X., & Yin, F. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i27.3297 · Cited by 31
Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting
Dai, X., & Zhu, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5491 · Cited by 29
The role of non-hematopoietic stromal cells in the persistence of inflammation
Barone, F., Nayar, S., & Buckley, C. D. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00416 · Cited by 32
“By using a FAP-DTR mice, in which deletion of FAP + fibroblasts is induced upon diphteria toxin administration, Kraman et al. (2010) have shown that depletion of FAP-expressing cells in Lewis lung carcinoma and pancreatic ductal adenocarcinoma causes rapid hypoxic necrosis of both tumor and stromal…”
MethodMeasuring and modelling tumour heterogeneity across scales
Beeghly, G. F., Shimpi, A. A., Riter, R. N., & Fischbach, C. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00087-9 · Cited by 30
4(3H)-Quinazolinone: A Natural Scaffold for Drug and Agrochemical Discovery
Chen, K., Wang, S., Fu, S., Kim, J., Park, P., Liu, R., & Lei, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062473 · Cited by 30
“…evaluated their antiproliferative effects on a panel of tumor cell lines including It plays a regulatory role in the expression of matrix metalloproteinases (MMPs), which are responsible for degrading the extracellular matrix, a process essential for cancer invasion and metastasis [100–102].”
License for destruction: Tumor-specific cytokine targeting
Johansson, A., Hamzah, J., & Ganß, R. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.10.002 · Cited by 30
Emerging Biomarkers as Predictors to Anti-Pd1/PD-L1 Therapies in Advanced Melanoma
Loo, K. L., & DAUD, A. I. (2016) · Immunotherapy · doi:10.2217/imt-2016-0039 · Cited by 30
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer
Suzuki, J., Tsuboi, M., & Ishii, G. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2019018 · Cited by 31
Highlights of Strategies Targeting Fibroblasts for Novel Therapies for Rheumatoid Arthritis
Chu, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846300 · Cited by 30
“In contrast, a recent study with genetic ablation of FAP in BM-MSC showed severe toxicity with anemia and weight loss (59).”
ResultGeng, F., Dong, L., Bao, X., Guo, Q., Guo, J., Zhou, Y., Yu, B., Wu, H., Wu, J., Zhang, H., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.07.008 · Cited by 28
Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer
Famta, P., Shah, S., Jain, N., Kumar, K. C., Bagasariya, D., Khatri, D. K., Raghuvanshi, R. S., Singh, S. B., & Srivastava, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121125 · Cited by 28
Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer
Nishida, T., Yoshitomi, H., Takano, S., Kagawa, S., Shimizu, H., Ohtsuka, M., Kato, A., Furukawa, K., & Miyazaki, M. (2015) · Pancreas · doi:10.1097/mpa.0000000000000499 · Cited by 30
“Enzymatic depletion of stromal matrix and anti–activated fibroblast treatment also showed antitumor effect.(9,16) These experimental results have thrust the concept of antistromal therapy into the forefront of pancreatic cancer treatment research as a promising therapeutic approach.”
BackgroundComplex metastatic niches: already a target for therapy?
Ordóñez‐Morán, P., & Huelsken, J. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.06.012 · Cited by 28
Bone marrow cells as precursors of the tumor stroma
Worthley, D. L., Si, Y., Quante, M., Churchill, M., Mukherjee, S., & Wang, T. C. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.03.006 · Cited by 29
“In another notable example, the ablation of FAP-expressing cells, which include cancer-associated pericytes and fibroblasts, impaired tumor growth due to promotion of anti-tumor immunity [23].”
Shao, H., Moller, M. G., Wang, D., Ting, A., Boulina, M., & Liu, Z. (2020) · Journal of Visualized Experiments · doi:10.3791/60660 · Cited by 29
Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection
Pires, A., Greenshields‐Watson, A., Jones, E., Smart, K., Lauder, S. N., Somerville, M. S., Milutinovic, S., Kendrick, H. D., Hindley, J. P., French, R., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0070 · Cited by 33
Tumor dormancy and the neuroendocrine system: an undisclosed connection?
Zappalà, G., Green, P. A., & Cole, S. W. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9400-x · Cited by 28
Badran, O., Cohen, I., & Bar‐Sela, G. (2025) · Cells · doi:10.3390/cells14171398 · Cited by 31
“…that FAP + stromal cells form a non-redundant, immunosuppressive compartment: genetic ablation of FAP + stromal cells (~2% of the tumor) restored immune control of tumor growth via IFN-γ /TNF-α /TNF-α -dependent mechanisms and induced rapid hypoxic necrosis of tumor and stromal cells [153].”
Xu, Y., Ma, J., Zheng, Q., Wang, Y., Hu, M., Ma, F., Qin, Z., Lei, N., & Tao, N. (2019) · Bioscience Reports · doi:10.1042/bsr20182171 · Cited by 27
Immunotherapy in Pediatric Solid Tumors—A Systematic Review
Marayati, R., Quinn, C. H., & Beierle, E. A. (2019) · Cancers · doi:10.3390/cancers11122022 · Cited by 29
Monslow, J., Todd, L., Chojnowski, J. E., Govindaraju, P. K., Assoian, R. K., & Puré, E. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.004 · Cited by 27
Killing the “BAD”: Challenges for immunotherapy in pancreatic cancer
Li, T., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188384 · Cited by 27
Organ Specificity and Heterogeneity of Cancer-Associated Fibroblasts in Colorectal Cancer
Miyashita, N., & Saito, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010973 · Cited by 28
Hazrati, A., Malekpour, K., Mirsanei, Z., Khosrojerdi, A., Rahmani-Kukia, N., Heidari, N., Abbasi, A., & Soudi, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1280601 · Cited by 29
Meng, M., Wang, W., Yan, J., Tan, J. Y., Liao, L., Shi, J., Wei, C., Xie, Y., Jin, X., Yang, L., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-4825-4 · Cited by 28
The Transcription Factor Hif-1 Enhances the Radio-Resistance of Mouse MSCs
Calvo‐Asensio, I., Dillon, E., Lowndes, N. F., & Ceredig, R. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00439 · Cited by 28
“…(Hanahan and Coussens, 2012; Kidd et al., 2012) where they are transformed into CAFs and promote tumorigenesis through various mechanisms (Kraman et al., 2010; Hanahan and Weinberg, 2011; Cuiffo and Karnoub, 2012; Hanahan and Coussens, 2012; Kidd et al., 2012; Barcellos-deSouza et al.,…”
BackgroundWeigert, A., Zheng, X., Nenzel, A., Turkowski, K., Günther, S., Strack, E., Sirait‐Fischer, E., Elwakeel, E., Kur, I.-M., Nikam, V. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33458-8 · Cited by 26
Cancer-Associated Fibroblast Heterogeneity in Malignancy with Focus on Oral Squamous Cell Carcinoma
Arebro, J., Lee, C.-M., Bennewith, K. L., & Garnis, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021300 · Cited by 27
Polymers showing cluster triggered emission as potential materials in biophotonic applications
Bresolí‐Obach, R., Castro‐Osma, J. A., Nonell, S., Lara‐Sánchez, A., & Martín, C. (2024) · Journal of Photochemistry and Photobiology C Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2024.100653 · Cited by 31
Kiss, K., Baghy, K., Spisák, S., Szanyi, S., Tulassay, Z., Zalatnai, A., Löhr, M. J., Jesenofsky, R., Kovalszky, I., & Firneisz, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128059 · Cited by 31
Shen, C., Kang, Y., Zhao, M., He, Y., Cui, D., Fu, Y., Yang, L., & Gou, L. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150712928 · Cited by 26
Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment
Dhas, N. L., Kudarha, R. R., Kulkarni, S., Soman, S., Navti, P. D., Kulkarni, J., Roy, A. A., Colaco, V., Raychaudhuri, R., Gupta, A., et al. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2910349 · Cited by 26
Sığırlı, S., & Karakaş, D. (2025) · Cancer Medicine · doi:10.1002/cam4.70788 · Cited by 25
Alpizar, Y. A., Chain, B., Collins, M. K., Greenwood, J., Katz, D. R., Stauss, H. J., & Mitchison, N. A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0985-7 · Cited by 26
Dominguez‐Gutierrez, P. R., Kwenda, E. P., Donelan, W., Miranda, M. A., Doty, A. L., O’Malley, P., Crispen, P. L., & Kusmartsev, S. A. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100026 · Cited by 25
Fibroblast activation protein-based theranostics in pancreatic cancer
Cheng, C., Yang, P., Sun, Y., Song, S., & Chen, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969731 · Cited by 25
“Howeve r , t h e t umor -p romo t ing and immunosuppressive activity of FAP fibroblasts have been demonstrated to suppress TNF signaling (27, 44, 45), thereby contributing to cancer–stroma–cancer interaction loop that promotes tumor progression (46).”
BackgroundResultInfluentialSclafani, F., Iyer, R., Cunningham, D., & Starling, N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.03.008 · Cited by 26
“[161] Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al.”
BackgroundBrunet, L. R., Hagemann, T., Gaya, A. M., Mudan, S., & Marabelle, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1112942 · Cited by 27
“tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs) and tumor-associated fibroblasts.(33,34)”
BackgroundMarei, H. E. S., Al-Thani, A., Caceci, T., Arriga, R., Sconocchia, T., Ottaviani, A., Lanzilli, G., Roselli, M., Caratelli, S., Cenciarelli, C., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.002 · Cited by 28
Contribution of bone marrow derived cells to the pancreatic tumor microenvironment
Scarlett, C. J. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00056 · Cited by 27
“The importance of an additional immunosuppressive cell type within the stroma was further defined through a recent study by Kraman et al. (2010), who demonstrated that a sub-population of stromal cells that express fibroblast activation protein (FAP) suppress the immune response and that abrogation…”
CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance
Coursier, D., & Calvo, F. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00931-z · Cited by 25
Chang, Y., Peng, H., Hu, C., Tien, S.-C., Chen, Y., Jeng, Y., & Chang, M. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13442 · Cited by 24
Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study
Huang, W., Pang, Y., Liu, Q., Liang, C., An, S., Wu, Q., Zhang, Y., Huang, G., Chen, H., Liu, J., et al. (2023) · Research · doi:10.34133/research.0282 · Cited by 28
Lv, B., Xie, F., Zhao, P., Ma, X., Jiang, W. G., Yu, J. Q., Zhang, X., & Jia, J. (2016) · PubMed · Cited by 24
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.